DUO-E: progression-free survival by clinical factors

Previously, the randomized, phase III DUO-E trial demonstrated a statistically significant benefit in progression-free survival (PFS) with a combination of carboplatin/paclitaxel (CP) and durvalumab followed by durvalumab ± olaparib compared to CP alone in the first line treatment of patients with newly diagnosed stage III/IV or recurrent endometrium cancer. During ESMO 2024, results were presented of an exploratory analysis of this trial looking at the effect on PFS in function of baseline clinical factors (i.e., age, BMI, ECOG performance status, prior chemotherapy, prior surgery and prior radiotherapy).

In the dMMR subpopulation, the durvalumab-based regimen showed a consistent clinically meaningful PFS benefit across all evaluable key clinical factors. This was also the case in the pMMR subpopulation except for patients who received prior chemotherapy. In contrast, with the addition of olaparib maintenance to durvalumab, CP plus durvalumab followed by durvalumab plus olaparib showed consistent enhanced PFS benefit versus CP across all subgroups.